Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PCL470 > Antimicrobials 2 - Antivirals > Flashcards

Antimicrobials 2 - Antivirals Flashcards

1
Q

Fungi: what do they include, feed on, reproduction, pharma relevance?

A
  • mold, mushrooms, yeast
  • feed on decomposing organic matter
  • reproduce sexually and asexually through spores
  • source of antibiotics (ex. penecillins) and other drugs
  • can symbiotic (lichen) or pathogenic (candidias)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What kind of cells are fungal cells? What are they similar to? What is in their cell wall?

A
  • eukaryotic (have nucleus)
  • similar to plant cells –> membrane, cell walll, nucleus, mitochondira, cytoplasm
  • chitin (instead of cellulose) and glucan and manoproteins –> only organism to have chitin and glucan in cell wall
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

history of antifungals

A
  • pre 1990s - home remeides of vinegar and gynpowder
  • early 1990s - general antiseptic gentian violet that binds to thioredoxin (protein in redox cycle of fungi that results in death if malfunctions)
  • first true antifungal: Amphotericin B (polyene) from soil bacteria in 1955
  • flucytosines (1970), azoles (1990), echinocanids (2000)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What do antifungals target?

A
  1. cell wall/membranr
  2. fungal DNA
  3. protein synthesis
  4. essential cellular processes
  5. virulence factors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do fungi acquire resistance? And how is this different from bacteria?

A
  1. block drug entry
  2. pump it out
  3. metabolize it
  4. mutate drug target
  5. avoid the pathway

but there is no transformation or conjugation because they dont have a mechanism for DNA transfer –> resistance grows slower than in bac

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the 5 antifungals?

A
  • amphotericin B
  • nystatin
  • fluconazole
  • griseolfulvin
  • flucysteine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Amphotericin B

A

What is it?
- Naturally occuring antifungal

Use
- blastomyces respiratory disease
- serious infections only

MOA
- binds directly to ergosterol in fungal cell wall and causes permeability –> leakage
- fungocidal

PK
- not orally bioavailable but is okay in the gut
- administered IV or lipid formulation

ADR
- toxi effects are dose dependent
- low TI (can bind cholesterol)
- hypotension
- anorexia
- kidney/liver damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Nystatin

A

What is it?
- polyene antifungal made from streptomyces bacteria

Treatment
- candida, oral thrush
- broad spectrum

MOA
- directly binds to ergosterol (fungal specific sterol) in cell membrane and causes permeability by forming TM pore–> leakage
- fungicidal

PK
- not orally bioavailable (large polyene striucture)
- administered topically or for GI –> not absorbed

  • good safety profile
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

fluconazole

A

What is it?
- synthetic azole antifungal - has azole rings

Treatment?
- oral trush and yeast infection
- broad spectrum

MOA?
- blocks ergosterol fluidity by blocking 14-demethylase (CYP450) that catalyzes lanosterol into ergosterol
- causes permeability and leakage
- fungicidal

PK?
- water soluble and very bioavailable
- administered orally and IV

ADR? Safety?
- very safe because we use HMG-CoA reductase –> selective
- minor GI issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

griseolfulvin

A

What is it?
- naturally produced antifungal

Treatment?
- nail and systemic infection

MOA?
- directly binds to tublin and leads to impaired microtubules –> blocks mitosis/replication
- fungistatic

PK?
- orally admin for superficial infections

ADR? Safety?
- sunlight sensitivity, yellowing of skin, liver damage, links to cancer –> can be used to treat cancer?
- slightly more selective for fungal tubulin but can also induce mutations in humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

flucytosine

A

What is it?
- synthetic base analogue

Treatment?
- systemic infections
- combination therapy for serious infections

MOA?
- prodrug converted by cytidine deaminase to 5-fluorouracil –> converted to NTP –> blocks DNA/RNA synthesis
- fungistatic

PK?
- orally bioavailable

ADR? Safety?
- blood count
- liver/kidney damage
- not safe in pregnancy
- possible carcigonen –> 5FU is toxic to human cells (used in chemo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Side effects and contraindications of antifungals

A
  1. toxicity and DNA damage
    - DNA damage from nucleotide analogues that can be incorporated into DNA of human cells (FLYCYTOSINE, GRISEOFULVIN)
    - liver and kidney toxicity (AMPHOTERICIN B)
  2. allergic reaction
    - mild to serious
    - specific to drug
  3. GI issues - from nausea to diarrhea
  4. Pregnancy
    - FLUCYTOSINE AND GRISEOFULVIN NOT OKAY
    - FLUCONAZOLE was thought to be okay but new evidence suggests increased risk of miscarriage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is a virus? What is its replication cycle? What genomes they that have?

A
  • small particle containing RNA or DNA and capsid and sometimes envelops proteins
  • not alive and reliant on host cell for replication and metabolism

replication cycle
attachement –> prenetration –> uncoating –> replication –> assembly –> release (lytic vs lysogenic)

genomes
- ssRNA, ssDNA, dsDNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how do viruses interact with the host genome

A
  1. transiently - non permanent and non intergarting
  2. permanent but not integrating: episome - an extra chromosome piece that replicates independently
  3. permanently
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how are viruses classified

A
  • genetic component (DNA/RNA)
    -morphology
  • mode of replication
  • host: tropism - narrow means they can only go into one or two tissues, broad means they can go into many
  • disease they cause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do RNA viruses interact with the host genome?

A
  • ssRNA and are non integrating ex SARS Cov 2
  • retrovirus that uses reverse transcriptase to integrate into the host DNA ex. HIV 1
  • dsRNA ex Reovirus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

how does RT integrate into the genome?

A
  • makes ssDNA from RNA
  • degardes RNA strand and copies the DNA to form dsDNA
  • goes into the nucleus and integrase helps with integration
  • uses LTR to input DNA into host genome
18
Q

Which viruses are DNA based? How are they categorized?

A

dsDNA: bacteriophage, adenovirus, HSV1/2
- dsDNA viruses can be non-permanent or permanent on episomes (ex. HSC1/2 can be latent or lytic)

ssDNA virsues: parovirus
- usually affects children and canines
- more mature immune systems dont get infected by ssDNA viruses

19
Q

targets of antivirals

A
  1. membrane/envelope - prevent entry and fusion
  2. viral DNA/RNA - polymerase or RT
  3. proteases
  4. glycoenzymes
  5. increase the defences of human cells
20
Q

What are the 5 antivirals?

A

docosanol
acyclovir
zivovudine
nirmatrelvir
amantidine

21
Q

Docosanol

A

What is it?
- emulsifying agent (thickening) - very long lipid with alcohol group

Treatment?
HSV1 cold sore

MOA?
- inhibits the fusion of the viral envelope to the human membrane by directly inserting into the membranr and altering it in a way that blocks fusion
- no resistance!! –> new paradigm –> protecting YOU

PK?
- not orally bioavailable or systemic use
- only for topical infections HSV1 cold sore

ADR?
- low topical absorption
- very safe

22
Q

acyclovir

A

What is it?
- synthetic purine analogue

Treatment?
- HSV1/2, varicella, EBV/CMV

MOA?
- thymidine kinase in virus converts prodrug to monophospahte –> tripphospahte NTP by host kinase –> integrates into DNA and causes chain termination
- our cells don’t have thymidine kinase so we are safe –> selective

PK?
- topical
- oral (prodrug increases absorption)
- IV
- good distribution

ADR?
- safe unless activated in non infected cells

23
Q

zidovudine

A

What is it?
- thymidine nucleoside analogue

Treatment?
- against retroviruses, HIV

MOA?
- prodrug converted to triphosphate by thymidine kinase –> inhibits reverse transcriptase by competing with natural NTPs –> chain termination –> inabilityt o produce DNA and blocks integration

PK?
- orally bioavaiulable

ADR?
- complications in bone marrow
- act on mitochondrial DNA pol

24
Q

nirmatrelvir

A

What is it?
- peptidomimetic

Treatment?
- covid 19

MOA?
- inhibits 3C like protease of SARS COV 2 –> competitive inhibitor that blocks viral replication (dummy substate for protease)
- (3C like protease is reposible for cleacing large pro-proteins into individual proteins)

PK?
- orally bioavailable

ADR?
- generallt well tolerated
- rebound effect

25
Q

amantidine

A

What is it?
- tricyclic amine

Treatment?
- influenza A

MOA?
- blocks M2 ion channels in envelope imporatnt in viral uncoating envelope and insertion of protein into in host membrane for genetic delivery–> blocks replication

PK?
- orally bioavailable

ADR?
- CNS effects
- teratogenic
- resistance due to mutations of M2 channel

26
Q

Antiviral resistance mechanisms

A
  • high mutation rates and are produced in high numbers –> prone to evolution
  • resistance arises from
  • mutations in target proteins that block drug action
    -mutations in membrane envelope proteins
27
Q

side effects and contradindications of antivirals

A
  1. toxicity and DNA damage - nucleotide analogues release and incoroprated into DNA of health human cells, liver toxicity for AZT
  2. allergic reactions
  3. GI issues
  4. pregnancy - most safe, but drug dependent
28
Q

How do traditional vaccines work

A
  • contain attenuated or inactiated virus or a purified recombinant protein
  • viral peptide fragments are captured and expressed on antigen presenting cells (APCs)
  • APCs activate T and B cells –> cytotxic T cells and plasma cells –> antibodies and memory cells
29
Q

How do next-generation nucleic acid vaccines work

A
  • contain DNA or mRNA encoding for a specific protein from the virus and transfered into a plasmid
  • delivered in a safe virus or chemical reagent
  • when inside the cell DNA –> mRNA –> protein
  • goal is to directly target APC cells so that the protein is expressed on the surface (don’t need phagocytosis anymore)
30
Q

What is SARS COV 2

A
  • severe acute respratory syndrome coronavirus 2
  • ssRNA vaccine
  • uses RNA-dependent RNA-polymerase for replication
  • has 29 proteins
  • uses spike protein to bind to ACE2 receptors on surface of cells - lung tissue has a lot of these
31
Q

how do the COVID vaccines work?

A
  • use a lipid nanoparticle to package modified RNA (pseudouridine) which encodes teh spike protein
  • BioNTech uses RNA/LPX that targets dendritic cells
  • dendritic cells present the protein to B and T cells
32
Q

resistance to COVID-19 vaccines

A
  • evolutionary pressure –> selection of mutations in the spike protein
  • if the protein changes by 6-8 AA then teh antibody can’t clear it –> resistance
33
Q

Concerns and contraindications with vaccines

A
  1. allergic reaction - rare and to components of vaccine
  2. off target immune reaction/autoimmune reaction - antibodies generated form vaccine cross react with targets on human cells
  3. infection - only an issue with attenuated or partially inactived vaccines, if immune system compromised it might lead to infection
  4. pregnancy - only an issue with attenuated and live vaccines causing risk to fetus
34
Q

What are antibodies?

A
  • match between APC and B cell receptor stimulates proliferation of B cell –> matures into plasma cell –> secretes antibodies
  • antibody antigen complexes are specific
  • contain fixed structural region and variable region for targeting antigens
35
Q

How are recombinant antibodies produced?

A
  1. identify antibody from library –> immunize rabits and collect serum (natural diversity)/or perfrom an in vitro phage display/or in silico –> this gives monoclonal antibody
  2. scale up production - can be performed using expression systems inclusing mammalian or insect cells, yeast, etc
36
Q

How do monoclonal antibodies function as antivirals and what is their PK?

A

bind to
- host viral receptors to block entry
- protein in free virus
- viral epitopes expressed on host cell –> stimulates secondary effector cells to activate B/T cells

PK - not orally bioavailable (stomach pH and proteases) - must be injected
- half life is days to weeks

37
Q

Examples of antiviral monoclonal antibodies

A
  1. palivizumab: binds to virus F protein on RSV envelope to prevent fusion
  2. ibalizumab: binds to CD4 T cell receptors on HIV to block entry
  3. REGEN-COV: made of 2 mAb and binds to 2 epitopes of the COV spike to block binding to ACE2 Rs, admin subcutaenously after exposure
38
Q

Hurdles and contraindications with antibody therapies (5)

A
  1. difficult to produce and purify: have to use expression systems and purify the cellular contaminants
  2. can only administer with injection
  3. can only be used as a prophylatic or in early stage of infection
  4. immune reaction/allergy
  5. pregnancy - can pass pregnancy barrier
39
Q

CRISPR/CAS9 as treatment for HIV

A

goal: target sequence of viral DNA inside cell and leave it to block replication

CAS9
- 20pb programmable guide RNA and cleaves dsDNA
- excellent specificity, only cuts in cis

HIV: integrated retrovirus

Cas9 can
- disrupt replication genees (1 guide RNA)
- cut out the HIV provirus from host genome (cure) (2 guide RNAS)
- edit host cell so they lack the receptor for HIV to bind

strategy: delivered using safe virus or lipid nanoparticle

40
Q

CRISPR/Cas13 therapy for COV

A

COV: ssRNA virus

Cas13
- 30bp programmable guide RNA that cleaves ssRNA
- trans collateral RNA cleavage after cis cleavage (only in bacteria or viruses)
- can use it to cleave viral RNA and block replication –> no collateral cleavage is observed in mammalian cells

strategy: Cas13 as protein or NA with RNA into cell using safe virus or lipid nanoparticle

41
Q

Contraindications with CRISPR/Cas antiviral therapies

A
  1. viral escape/evolution stimulation
    - resistance due to mutations in spacer sequence that blocks Cas from cutting –> viruses that have this can be selected and amplified
    - cleavage can stimulate this too)
  2. delivery - difficult to get system into all virally infected cells
  3. immune reactions to Cas if introduced into systemic circualtion
  4. human genome editing: off target DNA and RNA cleavage of similar human sequences if the enzyme escaped into human cells

PCL470 (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions